LTRN Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
3.5M
+3.0%
3.4M
-19.0%
4.2M
-3.4%
4.3M
-6.5%
4.7M
R&D
1.8M
+3.8%
1.7M
-37.2%
2.7M
+12.6%
2.4M
-20.6%
3.1M
SG&A
1.7M
+2.2%
1.7M
+15.3%
1.5M
-23.8%
1.9M
+20.8%
1.6M
Operating Income
-3508090
-3.0%
-3405247
+19.0%
-4202762
+3.4%
-4349800
+6.5%
-4651900
EBITDA
-3504339
-3.0%
-3401394
+19.0%
-4198659
+3.4%
-4345698
+6.5%
-4647399
Net Income
-7072124
-112.4%
-3329171
+18.3%
-4074217
+2.5%
-4177423
+3.5%
-4331015
EPS (Basic)
$-0.57
-90.0%
$-0.30
+16.7%
$-0.36
+7.7%
$-0.39
+2.5%
$-0.40
EPS (Diluted)
$-0.57
-90.0%
$-0.30
+16.7%
$-0.36
+7.7%
$-0.39
+2.5%
$-0.40
Shares (Diluted)
12.4M
+10.4%
11.3M
+0.6%
11.2M
+3.3%
10.8M
+0.5%
10.8M
Lantern Pharma (LTRN) โ€” Financials